Aardvark Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aardvark Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($16.32M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($14.37M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($9.31M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.18M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.45M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.18M) | May 14, 2025 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($17.70M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($15.85M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.47M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.09M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($6.07M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.17M) | May 14, 2025 |